Preimplantation Genetic Screening/Diagnosis (PGS & PGD) consists of the biopsy of several cells per embryo, followed by its genetic diagnosis through different techniques, and the subsequent replacement to the patient or freezing, of only those embryos classified by genetic diagnosis as normal. Since the early 1990s, the standard preimplantation genetics testing methods, using PGS/PGD techniques, have previously only allowed for the evaluation of 9 to 12 chromosomes out of a total of 23 chromosome pairs in the human embryo cell. Today, Array Comparative Genomic Hybridization (aCGH), Microarray, and Next Gen Sequencing solve this problem by evaluating all 23 chromosome pairs, allowing completely screened normal embryos to be identified and transferred or frozen. The field of Preimplantation Genetics has been revitalized with the development of these newer technologies.
Preimplantation Genetic Diagnosis Background
As women get older, many of their eggs become genetically abnormal, causing infertility but also significantly increasing the risks for miscarriages and genetic birth defects. In vitro Fertilization (IVF) is the best fertility option so egg quality as well as embryo quality can be evaluated visually and then a few of the healthiest appearing embryos can be transferred to the uterus.
Furthermore, assessing some of the chromosomes of each normally developing embryo, for structural abnormalities (deletions) or abnormal numbers of chromosomes (aneuploidy), by Preimplantation Genetic Screening- PGS, has been available since the early 1990s. PGS can reduce the risk of miscarriage as well as the risk of many genetic birth defects with the subsequent transfer to the patient of those embryos classified by genetic diagnosis as normal. The technique involved the microscopic removal of generally a single cell from a day 3 developing embryo. Most normal embryos on day 3 have 5-8 cells, so removal of one cell usually did not disrupt the embryo. Once a single cell (a blastomere) is removed, the cell is fixed on a glass slide for chromosomal analysis… analyzed using a technique called fluorescence in situ hybridization (FISH) Two days later, one or two of the genetically normal embryos were transferred to the uterus on day 5. Several recent studies have confirmed that the biopsy methods employed during PGS are critical for providing accurate results without harming the embryos being tested. Day 3 embryo biopsy, combined with PGS, can improve IVF success rates if biopsy methods and PGS analysis are each done by experienced embryologists and geneticists, but may produce negative results if either of these processes is performed in a suboptimal manner by inexperienced hands.
The 9 to12 chromosomes chosen for testing (usually Chromosomes # 13 14 15 16 17 18 21 22 X and Y) account for over 90% of the genetic miscarriages and birth defects. For example, Down’s syndrome is caused by an extra # 21 chromosome (Trisomy 21). Aneuploidy (any abnormal number of chromosomes….missing or extra) increases dramatically as women age.
The most common situations for recommending PGS include:
These older PGS methods utilizing the day 3 biopsy of a single cell (usually representing all cells of the 5-8 cell embryo) were associated with an error rate of 5%, with almost all errors attributable to mosaicism (the presence of one or more chromosomally different cell lines within the same embryo). No method based upon screening of a single cell on day 3 can avoid a small error rate due to mosaicism. Now with the newer improved techniques, day 3 biopsies are no longer done, only day 5 (see below).
In addition, there are numerous genetic diseases secondary to ‘single gene disorders’ that result from mutations affecting individual genes on a chromosome. Preimplantation Genetic Diagnosis, or PGD, involves assessing a given chromosome for these single gene abnormalities by doing a day 3 embryo biopsy of a single cell. Using polymerase chain reaction (PCR), fluorescent PCR and DNA sequencing, the geneticists in the PGD laboratory can examine each developing embryo to identify the absence or presence of these specific genetic disorders.
The most common indications for recommending single gene PGD include:
New Frontier: Microarray, aCGH, and Next Gen Sequencing
Complete karyotype chromosome analysis (all 23 pairs) of day 5 blastocyst-stage embryos is now clinically available using aCGH, Microarray and Next Gen. aCGH innovative technology uses whole genomic amplification of the DNA from the embryo biopsy, array technology, followed by fluorescent green labeling of the sample DNA, then hybridization with normal DNA, fluorescently labeled red. Images are collected by specialized software which compares intensities between red and green for each chromosome, generating a molecular karyotype. Thus, aCGH can identify an ‘imbalance’ in chromosomal material and detect all trisomies and monosomies (aneuploidy) and some large structural translocation imbalances. Microarray and Next Gen Sequencing (newest methodology) utilize different technologies to accomplish a similar, more comprehensive evaluation.
Advantages of aCGH or Microarray or Next Gen for aneuploidy or single gene testing on day 5 blastocyst-stage embryos:
After day 5 blastocyst biopsies are performed at FCI, the embryos are then frozen (vitrified) to allow for the lengthy comprehensive chromosome analysis. Transferring the thawed embryos takes place in a subsequent cycle, at the time of optimal endometrial receptivity. Utilization of this approach requires a significant level of expertise in numerous procedures - day 5 blastocyst cultures, new vitrification (fast freeze) techniques and embryo transfer in a subsequent cycle.